A 2009 rat study by Sever et al
Every patient in these groups deserves a real conversation about whether GLP-1 therapy fits their values and goals
The platform reported serving over 100,000 patients by 2023, leveraging virtual visits to reduce access barriers
Starr JI, Mako ME, Juhn D, Rubenstein AH (1978) Measurement of serum proinsulin-like material: cross-reactivity of porcine and human proinsulin in the insulin radioimmunoassay
Depending on the clinical picture, that typically includes: Relevant baseline bloodwork before starting IGF-1 dynamics where appropriate, so the response can be tracked rather than assumed Glucose and metabolic markers where relevant Follow-up adjustments based on results, tolerability, and goals A clear plan for duration and review rather than indefinite open-ended use This is also why CJC-1295 and Ipamorelin are often discussed alongside related options like Tesamorelin for visceral fat and metabolic goals